Diese Website verwendet Cookies, damit wir dir die bestmögliche Benutzererfahrung bieten können. Cookie-Informationen werden in deinem Browser gespeichert und führen Funktionen aus, wie das Wiedererkennen von dir, wenn du auf unsere Website zurückkehrst, und hilft unserem Team zu verstehen, welche Abschnitte der Website für dich am interessantesten und nützlichsten sind.
Exit highlight in Life Sciences: GreenGate Partners advises HTGF on the sale of Tubulis to Gilead Sciences
GreenGate Partners is pleased to have advised High-Tech Gründerfonds (HTGF) on the sale of its portfolio company Tubulis to Gilead Sciences.
Gilead has entered into a definitive agreement to acquire Tubulis, a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), for USD 3.15 billion upfront plus up to USD 1.85 billion in milestone payments. The transaction represents the highest-valued exit in HTGF’s history and the third unicorn exit in HTGF’s life sciences portfolio.
Following completion of the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, with its Munich site continuing to serve as a hub for ADC innovation.
The transaction highlights the importance of long-term partnership between investors and founders in translating scientific innovation into impactful therapies and meaningful value creation.
More Deal News
16. März 2026
Deal News – GreenGate Partners advises Qdrant on USD 50 Mio. Series B funding Round
4. März 2026
Deal News – GreenGate Partners berät amberra bei Finanzierungsrunde der nuuEnergy GmbH
19. Februar 2026
Deal News – GreenGate Partners advises on landmark German-Ukrainian defense joint venture
Advisors GreenGate Partners
Dr. Tobias Schönhaar, LL.M. (Bond) (Partner / Corporate)
Constantin Forstner (Senior Associate / Corporate)